# Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer

> **NCT06115733** · NA · NOT_YET_RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 56 (estimated)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** Fruquintinib、Capecitabine Tablets

## Key facts

- **NCT ID:** NCT06115733
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-28
- **Primary completion:** 2026-12-15
- **Final completion:** 2026-12-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06115733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06115733, "Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06115733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*